


**Product Name** : GB1211  
**Cat. No.** : PC-49544  
**CAS No.** : 1978336-95-6  
**Molecular Formula** : C<sub>19</sub>H<sub>16</sub>BrF<sub>3</sub>N<sub>4</sub>O<sub>4</sub>S  
**Molecular Weight** : 533.320  
**Target** : Galectin  
**Solubility** : 10 mM in DMSO



## Biological Activity

Selvigaltin (GB1211) is a highly potent, selective and orally active **Galectin-3** inhibitor with binding K<sub>d</sub> of 25 nM in FP assays.

GB1211 displays >100-fold selectivity over Galectin-1 as well as low CYP P450 inhibition, also shows no affinity against a panel of 87 different targets (enzymes, receptors, and ion channels).

GB1211 inhibits galectin-3 expression in human monocyte THP1 cells with IC<sub>50</sub> of 220.3 nM, inhibits TGFβ stimulated pro-fibrotic gene expression in human liver stellate cell line (LX2) in vitro.

GB1211 (2 mg/kg or 10 mg/kg bid, oral) reduces fibrosis in mouse CCl<sub>4</sub>-induced liver fibrosis model.

GB1211 is currently in clinical development as a novel, orally active therapy for liver fibrosis.

## References

Fredrik R Zetterberg, et al. *J Med Chem*. 2022 Oct 13;65(19):12626-12638.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com